Loading clinical trials...
Loading clinical trials...
To test the efficacy of CP-751,871 combined with docetaxel and prednisone in the treatment of prostate cancer that is refractory to hormone therapy
Keep your clinical trial research organized — questions to ask, what to expect, and key details.
Lead Sponsor
Pfizer
NCT06190899 · mCRPC (Metastatic Castration-resistant Prostate Cancer), Genital Diseases, Male, and more
NCT07225946 · Prostatic Neoplasms, Castration-Resistant
NCT04868604 · Prostatic Neoplasms, Castration-Resistant
NCT06547398 · Prostatic Neoplasms
NCT06751329 · Ovarian Neoplasms, Prostatic Neoplasms, and more
Pfizer Investigational Site
Los Angeles, California
Pfizer Investigational Site
New York, New York
Pfizer Investigational Site
Cleveland, Ohio
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Start free trial →Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions